Eli Lilly and Company’s (LLY) second-quarter 2024 results were exceptionally strong, beating estimates for earnings and sales.Moreover, adjusted earnings per share of $3.92 rose 86$11.3 billion rose 36% year over year.Strong demand for its successful GLP-1-based treatments, Mounjaro and Zepbound, and other key drugs, Verzenio and Taltz, pulled up the top line in the quarter. Almost all key drugs, Mounjaro, Zepbound, Taltz and Verzenio, beat expectations. Mounjaro and Zepbound t ...